Processa PharmaceuticalsPCSA
13F holders, Q4 2024 (December 31)8holders
2new positions
2sold out
$0.88avg. 13F price*
At the end of Q4 2024, 8 institutions reported holding Processa Pharmaceuticals Inc. (PCSA) in their 13F filings, unchanged from Q3 2024. 2 opened new positions and 2 sold out. The largest holders were HRT Financial LP ($28K), Vanguard Group Inc. ($22K) and Geode Capital Management, LLC ($20K).
- Company
- Processa Pharmaceuticals Inc.
- CUSIP
- 74275C304
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $37K |
| Exits | 2 | $119 |
All 13F filers, Q3 2024 → Q4 2024: 51,648 shares bought and 1,264 shares sold, net +50,384 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| HRT Financial LP | 0.00% | New | 31,971 | $28K |
| Vanguard Group Inc. | 0.00% | No change | 24,433 | $22K |
| Geode Capital Management, LLC | 0.00% | Add +11.6% | 21,982 | $20K |
| Composition Wealth, LLC | 0.00% | New | 10,000 | $9K |
| UBS Group AG | 0.00% | Add +1417.8% | 7,908 | $7K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -32.4% | 2,462 | $2K |
| Wells Fargo & Company | 0.00% | No change | 154 | $136 |
| Bank of America Corp. | 0.00% | Add +4.2% | 25 | $22 |
"% of holder's portfolio" is PCSA's weight in each manager's 13F, not the share of Processa Pharmaceuticals Inc. the manager owns.